Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

Incidence of chronic kidney disease among adults with prediabetes in the CURE-CKD registry, 2013-2020

Alicic RZ, Duru OK, Jones CR, Kornowske LM, Daratha KB, Reynolds CL, Pavkov ME, Koyama AK, Xu F, Nicholas SB, Neumiller JJ, Norris KC, Hennessey[...]

Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations

Lafayette RA, Charu V, Glassock RJ. Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations. Adv Ther. 2025 Mar 27. doi: 10.1007/s12325-025-03167-x. Epub ahead[...]

The End Kidney Deaths Act Risks Irreversible Harm to Organ Donation

Mueller TF, Matamoros MA, Danovitch GM, Nagral S. The End Kidney Deaths Act Risks Irreversible Harm to Organ Donation. JAMA. 2025 Mar 26. doi: 10.1001/jama.2025.2409.[...]